Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1-selected chemotherapy-naive patients with advanced NSCLC

被引：0
|
作者：
Herbst, R. S. [1 ]
de Marinis, F. [2 ]
Jassem, J. [3 ]
Spigel, D. R. [4 ]
Shankar, G. [5 ]
Mocci, S. [5 ]
Sandler, A. [5 ]
Lopez-Chavez, A. [5 ]
Li, S. [6 ]
Giaccone, G. [7 ]
机构：
[1] Yale Univ, Sch Med Med Oncol, Med Oncol, New Haven, CT USA
[2] Ist Europeo Oncol, Thorac Oncol, Milan, Italy
[3] Med Univ Gdansk, Oncol & Radiotherapy, Gdansk, Poland
[4] Sarah Cannon Res Inst, Lung Canc Res Program, Nashville, TN USA
[5] Genentech Inc, Clin Sci, San Francisco, CA 94080 USA
[6] Genentech Inc, Biostat, San Francisco, CA 94080 USA
[7] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
ANNALS OF ONCOLOGY | 2015年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
355TiP
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [1] Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC
    Mok, T. S. K.
    Cappuzzo, F.
    Jotte, R. M.
    Reck, M.
    Papadimitrakopoulou, V.
    Sandler, A.
    Waterkamp, D.
    Verret, W.
    Shen, Y.
    Socinski, M. A.
    ANNALS OF ONCOLOGY, 2015, 26 : 106 - 106
  • [2] Phase III clinical trials in chemotherapy-naive patients with advanced NSCLC assessing the combination of atezolizumab and chemotherapy
    Reck, M.
    Papadimitrakopoulou, V. A.
    Cappuzzo, F.
    Jotte, R.
    Mok, T. S. K.
    Sandler, A.
    Waterkamp, D.
    Coleman, S.
    Asakawa, T.
    Socinski, M.
    ANNALS OF ONCOLOGY, 2016, 27
  • [3] Phase III clinical trials of atezolizumab combined with chemotherapy in chemotherapy-naive patients with advanced NSCLC.
    Papadimitrakopoulou, Vassiliki
    Cappuzzo, Federico
    Jotte, Robert M.
    Reck, Martin
    Mok, Tony
    Sandler, Alan
    Waterkamp, Daniel
    Coleman, Shelley
    Sugitani, Yasuo
    Socinski, Mark A.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [4] IMpower110: Phase III trial of 1L atezolizumab in PD-L1-selected chemotherapy-naive NSCLC
    Jassem, J.
    de Marinis, F.
    Spigel, D. R.
    Lam, S.
    Mocci, S.
    Sandler, A.
    Lopez-Chavez, A.
    Deng, Y.
    Giaccone, G.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2017, 28
  • [5] IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1-Selected Chemotherapy Naive NSCLC Patients
    Herbst, Roy S.
    De Marinis, Filippo
    Jassem, Jacek
    Lam, Sivuonthanh
    Mocci, Simonetta
    Sandler, Alan
    Lopez-Chavez, Ariel
    Deng, Yu
    Giaccone, Giuseppe
    Spigel, David R.
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S304 - S305
  • [6] IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD-L1 Selected Chemotherapy-Naive NSCLC Patients
    De Marinis, Filippo
    Jassem, Jacek
    Spige, David
    Lam, Sivuonthanh
    Mocci, Simonetta
    Sandler, Alan
    Lopez-Chavez, Ariel
    Deng, Yu
    Giacconne, Giuseppe
    Herbst, Roy
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1299 - S1300
  • [7] First-Line Atezolizumab Plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Jotte, Robert M.
    Socinski, Mark A.
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    West, Howard J.
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Cappuzzo, Federico
    JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (11) : S302 - S303
  • [8] First-Line Atezolizumab plus Chemotherapy in Chemotherapy-Naive Patients with Advanced NSCLC: A Phase III Clinical Program
    Cappuzzo, Frederico
    Reck, Martin
    Papadimitrakopoulou, Vassiliki
    Jotte, Robert
    West, Howard
    Mok, Tony
    Sandler, Alan
    Mocci, Simonetta
    Coleman, Shelley
    Asakawa, Takashi
    Socinski, Mark
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1296 - S1297
  • [9] IMpower110: Phase III study on 1L atezolizumab (atezo) in PD-L1-selected chemotherapy (chemo)-naive NSCLC patients (pts)
    De Marinis, F.
    Jassem, J.
    Spigel, D. R.
    Lam, S.
    Mocci, S.
    Sandler, A.
    Lopez-Chavez, A.
    Deng, Y.
    Giaccone, G.
    Herbst, R. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [10] Atezolizumab for PD-L1-Selected Patients with NSCLC
    Horita, Nobuyuki
    Fukuda, Nobuhiko
    Kaneko, Takeshi
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (06): : 583 - 584
12345